Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2024-10-01
Last updated
2026-10-15

Condition(s) studied

Cow's Milk Allergy

Investigational drug(s) / intervention(s)

Experimental Extensively Hydrolyzed FormulaPlacebo Extensively Hydrolyzed Formula

Experimental Extensively Hydrolyzed Formula: Experimental powder formula

Placebo Extensively Hydrolyzed Formula: Placebo powder formula

Study summary

This is a multi-center, randomized, double-blinded, placebo-controlled food challenge to be conducted in infants and children with confirmed IgE-mediated cow's milk allergy (CMA), followed by a 7-day open feeding of the experimental formula.

Eligibility

Sex
ALL
Min age
3 Months
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: * Participant's parent(s) is/are willing for their child to undergo confirmatory testing or must have had at least one of the following within 6 months of enrollment: 1. Physician diagnosis of IgE-mediated CMA, according to the participant's clinical history (e.g. gastrointestinal symptoms, hives, respiratory symptoms or angioedema) AND, detectable serum milk-specific IgE \>0.7 kUᴀ/L or positive skin prick test wheal ≥5 mm; 2. Documentation of milk-specific serum IgE ≥15 kUᴀ/L or ≥ 5 kUᴀ/L if younger than 1 year; 3. Documented cow's milk skin prick test wheal ≥8mm; 4. Physician-supervised oral food challenge that elicited immediate, objective, allergic symptoms. * Participant's parent(s) agree for their child to stop oral steroid use within 14 days and antihistamine use within 7 days prior to confirmation of diagnosis and food challenges. * Participant had followed a strict cow's milk protein-free diet for at least 2 weeks prior to enrollment. * Parent(s) confirm their intention not to administer any products containing cow's milk protein during the study. * Participant is between 3 months and 12 years of age at enrollment. * Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study. Exclusion Criteria: * Participant is partially or exclusively breastfed at the time of enrollment. * Participant is consuming an amino acid-based formula due to failure on an extensively hydrolyzed formula. * Significant chronic medical diseases including major chromosomal or congenital anomalies, gastrointestinal diseases, or abnormalities other than CMA, immunodeficiencies, unstable asthma, eczema and/or food allergies treated with biologics (omalizumab or other monoclonal antibody), FPIES, eosinophilic esophagitis, and severe uncontrolled eczema. * Previous severe anaphylactic reaction to cow's milk within the last two years., * An adverse medical history or current condition that is thought by the investigator to have potential for effects on tolerance or the hypoallergenicity test. * Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent. * Participant is consuming baked milk products. * Use of and/or changing dose of high potency steroids. * Participant is treated with any oral immunotherapy (sublingual, subcutaneous, and epicutaneous) for any food allergy.

Primary outcome measure(s)

  • Food Challenge Reactions — Food Challenge 1 to Food Challenge 2 (within 14 days of the Food Challenge 1) (followed by 7 days of feeding the experimental formula at home.)
    Percent of positive food challenge reactions to the experimental formula administered to cow's milk allergic infants and children.

Trial sites (9)

FacilityCityRegionStatus
Phoenix Children's Phoenix Arizona Recruiting
Children's Hospital Colorado Aurora Colorado Completed
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois Recruiting
University of Michigan Food Allergy Clinic Ann Arbor Michigan Recruiting
University of North Carolina at Chapel Hill Chapel Hill North Carolina Recruiting
Cincinnati Children's Hospital Medical Center Cincinnati Ohio Recruiting
Cleveland Clinic Cleveland Ohio Recruiting
Nationwide Children's Hospital Columbus Ohio Recruiting
UT Southwestern Medical Center Dallas Texas Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06456541 on ClinicalTrials.gov ↗ ← All trials in the USA